세계의 반려동물 진단 시장 예측(-2029년) : 제품별, 용도별, 동물 유형별, 최종사용자별, 기술별, 지역별

The companion animal diagnostics market is projected to reach USD 4.55 Billion by 2029 from USD 2.99 Billion in 2024 at a CAGR of 8.8% during the forecast period. Favorable laws and ever-present availability of animal insurance, with more animals getting diagnostics-covered, would greatly contribute to the continued development of this market. In countries implementing regulation that forces a higher degree of veterinary expertise, pet owners tend to entrust their animals with doctors and get health check-up diagnostics done periodically. With pet insurance that includes diagnostics availability to a greater percentage of the population than before, due to this access to veterinary care is increased. Insurance companies can now offer plans that can cover diagnostic services like blood tests, imaging, and screenings in order to make it worthwhile to seek timely and preventive care. This trend will ensure healthy pets and further the diagnostic tools and services markets, through which it will provide for further development and growth in demand all over the sector.

"The consumables segment is accounted for the largest share of companion animal diagnostics market."

The global emergence of veterinary clinics and hospitals with diagnostic facilities has significantly enhanced the demand for consumables used in diagnostics. This has more-than-normal increased the demand for consumables test kits, imaging supplies, and reagents as more veterinary practices are equipped with advanced diagnostics. Superlatively, it is also indicative of a larger trend toward improving healthcare for pets, as pet owners continue to seek better veterinary services for accurate diagnosis of all diseases. On-the-rise number of specialized clinics and hospital businesses offering specific services adds to the use of consumables utilized for routine checkups, disease detection, and disease treatment monitoring. Availability of the most modern diagnostic equipment in veterinary settings not only improves accurate diagnosis, but also promotes regular testings which in turn puts a higher demand on consumables. All these reasons illustrate the strengthening of diagnostic capabilities in veterinary medicine as a potential reason for the continued growth of the overall global market for diagnostic products and services.

"Dogs holds the largest market share of companion animal diagnostics market."

The rapidly increasing diversity of dog breeds, each having unique genetic predispositions for different health conditions, is increasingly accentuating the need for breed-specific diagnostic tests. With breed-specific care becoming extremely popular among dog owners, so also have the avocations of veterinarians in spotting conditions that are more prevalent in certain breeds. These are a few diseases, including heart disease, hip dysplasia, and certain types of cancers, under which the patient is required to undergo specialized diagnostic techniques for early detection and effective management. Demand for such diagnostic tools and tests to detect these breed-specific phenomena has thereby opened the way for precise and personalized veterinary care. Now possible with improvements in genetic testing, veterinarians can provide more accurate screenings for early intervention and better health outcomes. As dog breeds become more popular, there is bound to be an upsurge for specialty diagnostic service relative to these genetic signs that will further impact the veterinary diagnostics markets.

"North America to witness the substantial growth rate during the forecast period."

The companion animal diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries based on the region type. In 2023, the Asia Pacific region is projected to exhibit the highest CAGR during the forecast period. However, North America accounts for the largest market share of the companion animal diagnostics market in 2023. Due to increasing incidences of pet health issues such as cancer, diabetes, and kidney diseases, the demand for newer and advanced diagnostic tests will rise to detect and treat these diseases. Most of the pet owners in North America are now seeking quick and reliable diagnostics for better health outcomes for their pets. Some of the larger veterinary infrastructure and rising public interest in pet health have also spurred the use of these "diagnostic tools and technologies." The availability of ready pet insurance that covers most of the diagnostic services has also increased access to quality care for pet owners. Thus, because the number of pets suffering from chronic and infectious diseases keeps climbing, market demand for companion animal diagnostics will only continue to grow, further bolstering North America's superiority in the global market.

A breakdown of the primary participants (supply-side) for the companion animal diagnostics market referred to for this report is provided below:

• By Company Type: Tier 1-45%, Tier 2-30%, and Tier 3-25%
• By Designation: C-level-35%, Director Level-25%, and Others-40%
• By Region: North America-40%, Europe-20%, Asia Pacific-25%, Latin America- 10%, and Middle East and Africa- 3% and GCC Countries- 2%

Prominent players in this market include IDEXX (US), Zoetis Services LLC (US), Mars, Incorporated (US), FUJIFILM Corporation (Japan), bioMerieux (France), Thermo Fisher Scientific Inc (US), Virbac (France), Neogen Corporation (US), INDICAL BIOSCIENCE GmbH (Germany), IDvet (France), Randox Laboratories Ltd. (UK), Shenzhen Mindray Animal Medical Technology Co., LTD. (China), Bionote USA Inc. (US), Boule (Sweden), EUROIMMUN Medizinische Labordiagnostika AG (Germany), Biopanda Reagents Ltd (UK), Nova Biomedical (US), Megacor Veterinary Diagnostics (Austria), Eurolyser Diagnostica GmbH (Austria), URIT MEDICAL ELECTRONIC CO., LTD. (China), Fassisi GmbH (Germany), Swissavans AG (Switzerland), Skyla Corporation (Taiwan), Ring Biotechnology Co Ltd (China), and Alvedia (France).

Research Coverage:

The market study covers the companion animal diagnostics market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by product, technology, animal type, application, end user and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

• Analysis of Market Dynamics: Drivers (expansion in companion animal population, increasing demand for pet insurance and growing animal health expenditure, growing number of veterinary practitioners) restraints (rising pet care costs) opportunities (growing demand for rapid tests and portable instruments for POC diagnostics, utilization of AI and ML for enhanced disease diagnosis), and challenges (shortage of veterinary practitioners in emerging markets)
• Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new product launches in the companion animal diagnostics market.
• Market Development: Comprehensive information on the lucrative emerging markets, components, demographics, end-user, and region.
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the companion animal diagnostics market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the companion animal diagnostics market like IDEXX (US), Zoetis Services LLC (US), Mars, Incorporated (US), FUJIFILM Corporation (Japan), bioMerieux (France).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED & REGIONS CONSIDERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 LIMITATIONS
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RISK ASSESSMENT
• 2.7 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 COMPANION ANIMAL DIAGNOSTICS MARKET OVERVIEW
• 4.2 COMPANION ANIMAL DIAGNOSTICS MARKET: REGIONAL MIX
• 4.3 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY & COUNTRY (2023)
• 4.4 COMPANION ANIMAL DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Expansion in companion animal population
    • 5.2.1.2 Increasing demand for pet insurance and growth in animal healthcare expenditure
    • 5.2.1.3 Growing number of veterinary practitioners
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Rising pet care costs
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing demand for rapid tests and portable instruments for POC diagnostics
    • 5.2.3.2 Utilization of AI and ML for enhanced disease diagnosis
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Shortage of veterinary practitioners in emerging markets
• 5.3 INDUSTRY TRENDS
  • 5.3.1 ADOPTION OF MULTIPLE TESTING PANELS
  • 5.3.2 OUTSOURCING OF VETERINARY DIAGNOSTIC TESTING SERVICES
• 5.4 DISEASE TRENDS
  • 5.4.1 ZOONOTIC DISEASES
  • 5.4.2 OBESITY & DIABETES
• 5.5 TECHNOLOGICAL ANALYSIS
  • 5.5.1 KEY TECHNOLOGIES
    • 5.5.1.1 Portable instruments
  • 5.5.2 COMPLEMENTARY TECHNOLOGIES
    • 5.5.2.1 Wearable health monitoring devices
  • 5.5.3 ADJACENT TECHNOLOGIES
    • 5.5.3.1 Rapid vet diagnostic kits
• 5.6 TRADE ANALYSIS
  • 5.6.1 TRADE ANALYSIS OF MEDICAL DEVICE PRODUCTS (HS CODE 9018)
  • 5.6.2 EXPORT DATA FOR COMPANION ANIMAL DIAGNOSTICS CONSUMABLES & INSTRUMENTS (HS CODE 9018)
  • 5.6.3 IMPORT DATA FOR COMPANION ANIMAL DIAGNOSTICS CONSUMABLES & INSTRUMENTS (HS CODE 9018)
• 5.7 PRICING ANALYSIS
  • 5.7.1 AVERAGE SELLING PRICE OF COMPANION ANIMAL DIAGNOSTICS, BY KEY PLAYER (2023)
  • 5.7.2 AVERAGE SELLING PRICE TREND OF IMMUNODIAGNOSTICS, BY REGION (2021-2023)
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.9 VALUE CHAIN ANALYSIS
• 5.10 ECOSYSTEM ANALYSIS
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 THREAT OF NEW ENTRANTS
  • 5.11.2 THREAT OF SUBSTITUTES
  • 5.11.3 BARGAINING POWER OF SUPPLIERS
  • 5.11.4 BARGAINING POWER OF BUYERS
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 SUPPLY CHAIN ANALYSIS
• 5.13 REGULATORY ANALYSIS
  • 5.13.1 REGULATORY LANDSCAPE
    • 5.13.1.1 North America
    • 5.13.1.2 Europe
    • 5.13.1.3 Asia Pacific
  • 5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.14 PATENT ANALYSIS
  • 5.14.1 PATENT PUBLICATION TRENDS FOR COMPANION ANIMAL DIAGNOSTICS
  • 5.14.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.15 KEY CONFERENCES & EVENTS, 2024-2025
• 5.16 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.16.2 BUYING CRITERIA
• 5.17 CASE STUDY ANALYSIS
  • 5.17.1 CASE STUDY 1: OPPORTUNITY ASSESSMENT FOR AUTOMATED IMMUNOASSAY ANALYZERS IN COMPANION ANIMAL IMMUNODIAGNOSTICS
  • 5.17.2 CASE STUDY 2: IDENTIFICATION OF INTESTINAL PARASITES IN PET DOGS
  • 5.17.3 CASE STUDY 3: INTRODUCTION OF PETLY PLANS BY IDEXX FOR HIGHER VOLUME OF PATIENT VISITS
• 5.18 ADJACENT MARKET ANALYSIS
  • 5.18.1 VETERINARY DIAGNOSTICS MARKET
  • 5.18.2 VETERINARY REFERENCE LABORATORY MARKET
• 5.19 UNMET NEEDS/END-USER EXPECTATIONS IN COMPANION ANIMAL DIAGNOSTICS MARKET
• 5.20 IMPACT OF AI/GEN AI ON COMPANION ANIMAL DIAGNOSTICS MARKET
• 5.21 INVESTMENT & FUNDING SCENARIO

6 COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 GROWING AWARENESS OF PREVENTIVE CARE TO DRIVE MARKET
• 6.3 INSTRUMENTS
  • 6.3.1 ADOPTION OF RAPID TESTS FOR INFECTIOUS DISEASE DIAGNOSTICS TO PROPEL MARKET

7 COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 CLINICAL PATHOLOGY
  • 7.2.1 INCREASING VOLUME OF CLINICAL TESTS FOR DISEASE DIAGNOSIS TO DRIVE MARKET
• 7.3 BACTERIOLOGY
  • 7.3.1 INCREASING PREVALENCE OF ZOONOTIC DISEASES TO DRIVE MARKET
• 7.4 VIROLOGY
  • 7.4.1 INCREASING INCIDENCE OF VIRAL OUTBREAKS TO SUPPORT MARKET GROWTH
• 7.5 PARASITOLOGY
  • 7.5.1 RISING PREVALENCE OF KENNEL COUGH AND LYME DISEASE TO FUEL UPTAKE
• 7.6 OTHER APPLICATIONS

8 COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE

• 8.1 INTRODUCTION
• 8.2 DOGS
  • 8.2.1 RISING PET DOG POPULATION TO DRIVE MARKET
• 8.3 CATS
  • 8.3.1 GROWING FOCUS ON R&D FOR FELINE CARE TO FUEL UPTAKE
• 8.4 HORSES
  • 8.4.1 INCREASING AWARENESS OF EQUINE HEALTH TO SUPPORT MARKET GROWTH
• 8.5 OTHER COMPANION ANIMALS

9 COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 DIAGNOSTIC LABORATORIES
  • 9.2.1 INCREASING VOLUME OF SAMPLE TESTS TO DRIVE MARKET
• 9.3 VETERINARY HOSPITALS & CLINICS
  • 9.3.1 RISING PET CARE EXPENDITURE TO FUEL MARKET
• 9.4 VETERINARY RESEARCH INSTITUTES & UNIVERSITIES
  • 9.4.1 FAVORABLE INDUSTRY-ACADEMIA COLLABORATIONS TO SUPPORT MARKET GROWTH
• 9.5 HOME CARE SETTINGS
  • 9.5.1 IMPROVED CARE AND COST EFFICIENCY TO PROPEL MARKET

10 COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY

• 10.1 INTRODUCTION
• 10.2 CLINICAL BIOCHEMISTRY
  • 10.2.1 CLINICAL CHEMISTRY ANALYSIS
    • 10.2.1.1 Reagents, clips, and cartridges
      • 10.2.1.1.1 Ability to customize chemistry diagnostic tests to fuel uptake
    • 10.2.1.2 Analyzers
      • 10.2.1.2.1 Increasing installations of clinical chemistry analyzers to drive market growth
  • 10.2.2 GLUCOSE MONITORING
    • 10.2.2.1 Blood glucose strips
      • 10.2.2.1.1 Growing focus on remote monitoring to drive market
    • 10.2.2.2 Glucose monitors
      • 10.2.2.2.1 Utilization of portable BGMs to drive market
    • 10.2.2.3 Urine glucose strips
      • 10.2.2.3.1 Measurement of ketone concentration to drive market
  • 10.2.3 BLOOD GAS ELECTROLYTE ANALYSIS
    • 10.2.3.1 Reagents, clips, and cartridges
      • 10.2.3.1.1 Detection of blood pH to fuel uptake
    • 10.2.3.2 Blood gas & electrolyte analyzers
      • 10.2.3.2.1 Determination of oxygen and CO2 in blood to boost demand
• 10.3 IMMUNODIAGNOSTICS
  • 10.3.1 LATERAL FLOW ASSAYS
    • 10.3.1.1 Rapid tests
      • 10.3.1.1.1 Increasing prevalence of infectious diseases and real-time monitoring to drive market
    • 10.3.1.2 Strip readers
      • 10.3.1.2.1 High adoption of in-house testing centers to fuel uptake
  • 10.3.2 ELISA TESTS
    • 10.3.2.1 High sensitivity to fuel uptake
  • 10.3.3 ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS
    • 10.3.3.1 Increasing number of allergy cases in pets to support market growth
  • 10.3.4 IMMUNOASSAY ANALYZERS
    • 10.3.4.1 Ability to handle large number of samples for immunoassay testing to boost demand
  • 10.3.5 OTHER IMMUNODIAGNOSTIC PRODUCTS
• 10.4 HEMATOLOGY
  • 10.4.1 CARTRIDGES
    • 10.4.1.1 Ability to measure hematocrit and hemoglobin levels in blood samples to drive market
  • 10.4.2 ANALYZERS
    • 10.4.2.1 Complete blood analysis performance evaluation to boost demand
• 10.5 URINALYSIS
  • 10.5.1 CLIPS & CARTRIDGES
    • 10.5.1.1 Detection of UTIs in cats, dogs, and equine to boost demand
  • 10.5.2 URINE ANALYZERS
    • 10.5.2.1 Rising technological advancements to support market growth
  • 10.5.3 URINE TEST STRIPS
    • 10.5.3.1 Qualitative evaluation of leukocytes and protein to drive market
• 10.6 MOLECULAR DIAGNOSTICS
  • 10.6.1 PCR TESTS
    • 10.6.1.1 Increasing laboratory usage in proteomics & genomics to fuel market
  • 10.6.2 MICROARRAYS
    • 10.6.2.1 Utilization of biochips in infectious disease diagnostics to support market
  • 10.6.3 OTHER MOLECULAR DIAGNOSTICS PRODUCTS
• 10.7 OTHER TECHNOLOGIES

11 COMPANION ANIMAL DIAGNOSTICS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Rising pet healthcare expenditure to drive market
  • 11.2.3 CANADA
    • 11.2.3.1 Growing awareness of pet health to propel market
• 11.3 EUROPE
  • 11.3.1 ECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Growing feline & canine population to drive market
  • 11.3.3 UK
    • 11.3.3.1 Stable increase in pet ownership and preventive measures against animal diseases to drive market
  • 11.3.4 FRANCE
    • 11.3.4.1 Technological expertise and innovative advancements in diagnostics to fuel uptake
  • 11.3.5 ITALY
    • 11.3.5.1 Increased pet adoption and enhanced availability of pet products to support market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Rising animal health expenditure and growing number of veterinary facilities to drive market
  • 11.3.7 BENELUX
    • 11.3.7.1 Increasing pet population in Benelux to fuel uptake
  • 11.3.8 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Rising cases of zoonotic diseases to drive market
  • 11.4.3 JAPAN
    • 11.4.3.1 Increasing demand for imported pet breeds to drive market
  • 11.4.4 INDIA
    • 11.4.4.1 Growth in animal healthcare industry to drive market
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Growing focus on pet insurance to boost demand
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Growing focus on animal well-being to boost demand
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Growth in small animal population to support market
  • 11.5.3 MEXICO
    • 11.5.3.1 Increasing adoption of advanced diagnostic technologies to fuel uptake
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 RELUCTANCE TO SPEND ON PET HEALTH TO RESTRAIN MARKET
  • 11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 11.7 GCC COUNTRIES
  • 11.7.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES IN IMPORTED BREEDS TO SUPPORT MARKET GROWTH
  • 11.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET
• 12.3 REVENUE ANALYSIS, 2019-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Technology footprint
    • 12.5.5.4 Product footprint
    • 12.5.5.5 Animal type footprint
    • 12.5.5.6 Application footprint
    • 12.5.5.7 End-user footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 R&D EXPENDITURE OF COMPANION ANIMAL DIAGNOSTICS COMPANIES
• 12.10 COMPETITIVE SCENARIO
  • 12.10.1 PRODUCT LAUNCHES
  • 12.10.2 DEALS
  • 12.10.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 IDEXX
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 ZOETIS SERVICES LLC
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches
      • 13.1.2.3.2 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 MARS, INCORPORATED
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Deals
      • 13.1.3.3.2 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 BIOMERIEUX
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 MnM view
      • 13.1.4.3.1 Key strengths
      • 13.1.4.3.2 Strategic choices
      • 13.1.4.3.3 Weaknesses & competitive threats
  • 13.1.5 FUJIFILM CORPORATION
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 MnM view
      • 13.1.5.3.1 Key strengths
      • 13.1.5.3.2 Strategic choices
      • 13.1.5.3.3 Weaknesses & competitive threats
  • 13.1.6 THERMO FISHER SCIENTIFIC INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
  • 13.1.7 NEOGEN CORPORATION
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
  • 13.1.8 VIRBAC
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
  • 13.1.9 BOULE
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches
  • 13.1.10 INDICAL BIOSCIENCE GMBH
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
  • 13.1.11 IDVET
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
  • 13.1.12 RANDOX LABORATORIES, LTD.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
  • 13.1.13 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
  • 13.1.14 BIONOTE USA INC.
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product launches
      • 13.1.14.3.2 Deals
  • 13.1.15 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 SKYLA CORPORATION
  • 13.2.2 EUROLYSER DIAGNOSTICA GMBH
  • 13.2.3 NOVA BIOMEDICAL
  • 13.2.4 FASSISI GMBH
  • 13.2.5 SWISS BIOTECH ASSOCIATION
  • 13.2.6 ALVEDIA
  • 13.2.7 BIOPANDA REAGENTS LTD.
  • 13.2.8 MEGACOR VETERINARY DIAGNOSTICS
  • 13.2.9 URIT MEDICAL ELECTRONIC CO., LTD.
  • 13.2.10 RING BIOTECHNOLOGY CO., LTD.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS